August 25, 2025 — Leads & Copy — Immix Biopharma, Inc. will present and host institutional investor meetings at the Stifel 2025 Healthcare Conference, held Nov. 11-13 at the Lotte New York Palace Hotel in New York, NY. The clinical-stage biopharmaceutical company is developing cell therapies for AL Amyloidosis and other serious diseases.
The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Stifel representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.
Immix Biopharma, Inc. (Nasdaq: IMMX) is developing cell therapies for AL Amyloidosis and other serious diseases. Its lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that filters out non-specific activation. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. Interim results were presented at ASCO 2025 in an oral presentation by Heather Landau, M.D. of Memorial Sloan Kettering Cancer Center. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
Contact: Mike Moyer, LifeSci Advisors, mmoyer@lifesciadvisors.com.
Company Contact: irteam@immixbio.com
Source: Immix Biopharma, Inc.
